Supernus Pharmaceuticals, Inc. (SUPN) SEC Filings & Earnings Calls

Dependence on single supplier for ONAPGO until second supplier approval, expected mid-2027.

“submitted a supplemental New Drug Application to the FDA for a second supplier for ONAPGO and continues to expect potential FDA approval of the second supplier by mid-year 2027.” · word for word

Merger completion risk: requires stockholder and regulatory approvals, and is subject to various conditions.

“risk that the proposed merger may not be completed in a timely manner or at all; the failure to obtain the required approvals” · word for word

Intangible asset impairment: $54.9M non-cash impairment charge for APOKYN, indicating potential product decline.

“non-cash $54.9 million intangible asset impairment charge related to APOKYN” · word for word

Merger integration risk: merger with Indivior may face execution challenges and regulatory hurdles.

“risk that the proposed merger may not be completed in a timely manner or at all; the failure to obtain the required approvals” · word for word

Merger completion risk: requires stockholder and regulatory approvals, and is subject to various conditions.

“risk that the proposed merger may not be completed in a timely manner or at all; the failure to obtain the required approvals” · word for word

Merger completion risk: requires stockholder and regulatory approvals, and is subject to various conditions including HSR and foreign investment clearances.

“Consummation of the Merger is subject to customary closing conditions, including... the receipt of the required approvals of the Company’s and Indivior’s respective stockholders; the expiration or termination of the waiting period applicable to the Merger under the Hart-Scott-Rodino Antitrust Improvements Act” · word for word

Increased leverage: $650M debt to fund special dividend may strain combined company's balance sheet.

“senior secured term loan facility in an aggregate principal amount of $650 million” · word for word

APOKYN sales decline and impairment

“APOKYN 6,323 12,820 (6,497) (51)%” · word for word

Generic erosion for Trokendi XR and Oxtellar XR

“Trokendi XR 8,411 11,193 (2,782) (25)%” · word for word

ONAPGO supply constraints

“On November 4, 2025, we announced that due to stronger than expected demand for ONAPGO, supplier constraints were impacting our ability to fully meet this demand.” · word for word

Merger execution risk

“The consummation of the Transactions is subject to various regulatory approvals and customary terms and conditions set forth in the Indivior Merger Agreement.” · word for word

Cash outflow of $33.4M; may impact near-term liquidity.

“Company obligated to pay $33.4M within 20 business days.”

Generic erosion for Trokendi XR and Oxtellar XR

“Decline in net product sales of Oxtellar XR and Trokendi XR due to generic erosion.” · word for word

Single-source supplier risk for ONAPGO

“We currently rely on single source suppliers to produce and package final dosage forms for ONAPGO.” · word for word

Pipeline failure risk (SPN-820)

“The study did not demonstrate a statistically significant improvement on the primary and secondary endpoints.” · word for word

Dependence on ONAPGO second supplier approval; potential delay could impact supply.

“Regulatory submission to FDA for second supplier for ONAPGO expected in Q3 2026, with potential approval by mid-year 2027.”

Declining sales of mature products (Trokendi XR, APOKYN, Oxtellar XR) may offset growth.

“Trokendi XR -26%, APOKYN -48%, Oxtellar XR -27% YoY.”

Share Dilution Risk

“the Board of Directors believes it is in our best interests to increase the number of shares available for making awards under the 2021 Plan by 4,000,000 shares” · word for word

Milestone payments up to $350M contingent on success; if Phase 2b study not successful, company has no further obligation.

“following completion of the Phase 2 Study, if the Company determines in its sole reasonable discretion that such study was not successful, the Company will have no further obligation to pursue milestone achievement or commercialization of the Compound.” · word for word

Drug pricing pressure from U.S. healthcare reform

“The Inflation Reduction Act ('IRA') of 2022 includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D, with varying implementation dates.”

Pipeline failure risk

“In February 2025, the Company reported topline results from a randomized double-blind placebo-controlled Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD) following four weeks of chronic daily dosing. The study did not demonstrate a statistically significant improvement on the primary and secondary endpoints.” · word for word

Generic competition risk

“The Company has entered into settlement agreements with third parties, permitting the sale of a generic version of Trokendi XR beginning in January 2023 and entitling the Company to receive royalties on those sales.” · word for word

ONAPGO supply constraint risk partially mitigated by resumption and second supplier.

“New patient initiation for ONAPGO resumed in Q1 2026; second supplier expected in 2027.” · word for word

Dependence on Biogen for ZURZUVAE collaboration revenue.

“Collaboration revenue from ZURZUVAE represents 50% of net revenues recorded by Biogen.”

Acquisition Integration and Cost Overrun

“Selling, general and administrative expenses increased to $179.7 million in Q3 2025 from $69.8 million in Q3 2024, reflecting costs associated with the Sage acquisition and commercialization of new products.”

Contingent Consideration Liability

“Contingent consideration loss (gain) of $7.7 million for the nine months ended September 30, 2025, compared to a gain of $6.5 million for the same period in 2024, indicating volatility in fair value estimates.”

Supply constraint for ONAPGO due to stronger than expected demand, impacting ability to initiate new patients.

“Due to stronger than expected demand for ONAPGO, supplier constraints are impacting the Company's ability to fully meet this demand.” · word for word